Stoke Therapeutics (STOK) EBITDA Margin (2022 - 2026)
Stoke Therapeutics (STOK) recorded quarterly EBITDA Margin of 813.31% in Q1 2026, up 80.28% quarter-over-quarter from 4125.32% in Q4 2025, and down 88452.0% on a YoY basis from N/an in Q1 2025.
Stoke Therapeutics (STOK) EBITDA Margin (2022 - 2026) Analysis & Trends
Stoke Therapeutics' EBITDA Margin history runs 5 years deep, the most recent figure standing at 813.31% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 88452.0% year-over-year to 813.31%; the TTM figure through Mar 2026 stood at 529.23% (down 55551.0% YoY), while the FY2025 annual figure was 3.36%, up 24041.0% from the prior year.
- EBITDA Margin was 813.31% for Q1 2026 at Stoke Therapeutics, up from 4125.32% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 71.22% in Q1 2025 to a low of 4125.32% in Q4 2025.
- Historically, EBITDA Margin has averaged 810.76% across 5 years, with a median of 734.89% in 2023.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin soared 90996 bps in 2024, then slumped 407757 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 768.88% in 2022, then decreased by 25 bps to 957.71% in 2023, then surged by 95 bps to 47.75% in 2024, then slumped by 8539 bps to 4125.32% in 2025, then soared by 80 bps to 813.31% in 2026.
- The last three EBITDA Margin figures came in at 813.31% (Q1 2026), 4125.32% (Q4 2025), and 357.38% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.95 Bn | - | -813.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -813.31% |
| Dec 31, 2025 | -4,125.32% |
| Sep 30, 2025 | -357.38% |
| Jun 30, 2025 | -168.51% |
| Mar 31, 2025 | 71.22% |
| Dec 31, 2024 | -47.75% |
| Sep 30, 2024 | -536.35% |
| Jun 30, 2024 | -532.19% |
| Mar 31, 2024 | -625.00% |
| Dec 31, 2023 | -957.71% |
| Sep 30, 2023 | -734.89% |
| Jun 30, 2023 | -1,226.72% |
| Mar 31, 2023 | -426.40% |
| Dec 31, 2022 | -768.88% |
| Sep 30, 2022 | -913.53% |
| Jun 30, 2022 | -781.31% |
| Mar 31, 2022 | -838.83% |